von Willebrand disease: what does the future hold?

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Von Willebrand disease (VWD) presents diverse clinical symptoms, complicating diagnosis and management.
• Current VWD treatments, including VWF concentrates and desmopressin, have seen little innovation in 30 years.
• Despite perceived effectiveness, VWD significantly impacts patient quality of life, especially for women.

Purpose of the Study:

• To explore innovative therapeutic strategies for von Willebrand disease (VWD).
• To address the unmet need for improved VWD treatments beyond current standards.
• To outline potential future treatment modalities for VWD patients.

Main Methods:

• Review of potential genetic approaches, including gene therapy and allele silencing.
• Discussion of protein-based strategies to enhance Factor VIII levels in specific VWD types.
• Exploration of antibody-based therapies targeting VWF degradation or endogenous levels.

Main Results:

• Identified gene therapy using dual-vector adenoassociated virus as a potential VWD treatment.
• Proposed protein-based strategies for increasing Factor VIII in VWD types 3 and 2N.
• Outlined antibody-based options for managing VWD types 2A and 1.

Conclusions:

• Future VWD treatments may involve advanced genetic, protein, and antibody-based therapies.
• Innovation is crucial to overcome VWD heterogeneity and improve patient outcomes.
• These strategies offer a path toward superior efficacy and better patient care for VWD.